Billionaire investor Steve Cohen, through his Point72 Asset Management, has recently made a notable shift in his hedge fund's portfolio. Public filings reveal a move away from high-performing artificial intelligence giants like Amazon and Nvidia, with a substantial increase in investment towards the medical device company, Boston Scientific. This strategic reallocation signals a potential change in market sentiment regarding AI's growth trajectory and underscores a belief in the long-term value of established healthcare entities.
Billionaire's Portfolio Rebalancing: Exiting AI for Healthcare
In a significant portfolio adjustment during the initial quarter of 2026, Steve Cohen's Point72 Asset Management dramatically reduced its holdings in artificial intelligence sector leaders Amazon and Nvidia, while simultaneously fortifying its position in Boston Scientific, a prominent medical device manufacturer. This strategic realignment, documented in recent 13F filings, indicates a potential shift in investment focus from the currently booming AI market to a more value-driven opportunity within the healthcare industry. While Amazon and Nvidia had experienced extraordinary growth over the past decade, their performance at the start of 2026 lagged the broader S&P 500 index. This plateauing, following years of significant gains (Nvidia's stock soared over 16,000% and Amazon over 560% in the last ten years), may have prompted Cohen to realize profits. The hedge fund trimmed its Amazon stake by 6% and its Nvidia position by a substantial 24% between the fourth quarter of 2025 and the first quarter of 2026. This divestment from leading AI stocks suggests a re-evaluation of the AI trade, possibly indicating a belief that early leaders may be ceding ground to infrastructure companies crucial for AI's underlying development, such as hydrogen fuel cell producers like Bloom Energy. Concurrently, Cohen significantly boosted his investment in Boston Scientific by 50% since the beginning of the year. This aggressive buying occurred despite a notable year-to-date decline in Boston Scientific's stock value, suggesting a strong conviction in the company's long-term potential as a value play. Boston Scientific, a long-standing leader in medical technology, generates 66% of its revenue from cardiac care and 34% from medical-surgical products. While the company's first-quarter 2026 organic sales growth was a robust 9.4%, its guidance for the remainder of the year projects a slowdown to as low as 5% for the second quarter and a revised downward earnings forecast from $3.43-$3.49 to $3.34-$3.41 per share. Despite this conservative outlook and the market's current cautiousness, Boston Scientific's products face consistent demand irrespective of economic fluctuations. The company's current valuation metrics further support a value investment thesis, with a price-to-sales ratio of 3.2x, significantly lower than its five-year average of 6x, and a price-to-earnings ratio of 19x, well below its long-term average of 64x. This suggests that the stock is currently undervalued, offering a compelling opportunity for investors like Cohen who are looking for long-term growth and eventual market correction.
This strategic move by Steve Cohen offers a fascinating insight into the dynamic nature of investment. It underscores the importance of not only recognizing growth opportunities but also understanding when to reallocate capital, even from previously stellar performers. The decision to invest heavily in Boston Scientific, a company currently facing a downturn but possessing strong fundamentals and a critical market position, highlights a belief in value investing and the cyclical nature of industry performance. For investors, this shift could serve as a valuable lesson in portfolio diversification and the potential for long-term gains by identifying undervalued assets with inherent strengths, even when short-term outlooks appear challenging. It prompts us to consider whether the rapid ascent of AI stocks might be reaching a point of consolidation, paving the way for other sectors, like healthcare, to offer more stable and attractive long-term returns.